Nanoparticle News and Research

RSS

In nanotechnology, a particle is defined as a small object that behaves as a whole unit in terms of its transport and properties. It is further classified according to size: in terms of diameter, fine particles cover a range between 100 and 2500 nanometers, while ultrafine particles, on the other hand, are sized between 1 and 100 nanometers.

An overview of AAPM annual meeting

AAPM is the premier organization in medical physics, a broadly-based scientific and professional discipline encompassing physics principles and applications in medicine and biology. Its membership includes medical physicists who specialize in research that develops cutting-edge technologies and board-certified clinical medical physicists who apply these technologies in community hospitals, clinics, and academic medical centers.

16 Jul 2010

Arsenic nanoparticle to combat aggressive type of breast cancer prevalent in young women

You can teach an old drug new chemotherapy tricks. Northwestern University researchers took a drug therapy proven for blood cancers but ineffective against solid tumors, packaged it with nanotechnology and got it to combat an aggressive type of breast cancer prevalent in young women, particularly young African-American women.

16 Jul 2010

Access announces agreement to develop oral formulation of proprietary injectable drugs

Access Pharmaceuticals, Inc., announced today that it has entered into a pre-licensing feasibility agreement with a leading biotechnology company to develop an oral formulation of its currently-marketed, proprietary injectable drugs. Access will utilize its proprietary Cobalamin Oral Drug Delivery Technology to develop oral formulations of the drug for pre-clinical testing.

15 Jul 2010

Highlights of AAPM 52nd meeting

The 52nd meeting of the American Association of Physicists in Medicine (AAPM) convenes from July 18 - 22, 2010 in Philadelphia, PA.

14 Jul 2010

Lectures on DermaVir to be presented at International Conference on Nanosciences & Nanotechnologies

Julianna Lisziewicz, PhD, President of Genetic Immunity, a biopharmaceutical company developing nanomedicine-based immunotherapies, is an invited speaker at this week's 7th International Conference on Nanosciences & Nanotechnologies in Ouranoupolis Halkidiki, Greece. The conference gathers front-line researchers, scientists and industry experts specialized in nanotechnology applications. Leading experts such as Dr. Lisziewicz are invited to present lectures covering the latest research in this rapidly progressing field.

12 Jul 2010

Midatech, Immunotope form joint venture to develop antigen based products for immune therapies

Midatech Group Ltd., a global leader for the design, development, synthesis and manufacture of nanomedicines, and Immunotope Inc, a biotechnology company focused on the development of immunotherapy products, today announced the formation of a joint venture Syntara LLC, to develop antigen based products for immune therapies to treat chronic viral infections and certain cancers.

12 Jul 2010

SurModics to present four scientific posters on drug delivery technologies at CRS Annual Meeting

SurModics, Inc., a leading provider of drug delivery and surface modification technologies to the healthcare industry, is participating at the 37th Annual Meeting and Exposition of the Controlled Release Society, July 10-14, 2010 in Portland, Oregon (booth #521).

9 Jul 2010

URI engineers develop new controlled drug delivery system using nanoparticles embedded in liposome

A new system for the controlled delivery of pharmaceutical drugs has been developed by a team of University of Rhode Island chemical engineers using nanoparticles embedded in a liposome that can be triggered by non-invasive electromagnetic fields.

9 Jul 2010

Scientists discover nanoparticle to deliver DNA with minimum toxic effect

In lab experiments, the researchers have found that this device, a vector, is able to deliver DNA deeply enough into a cell to allow genetic material to be activated - a critical step in gene therapy. This vector is between 2 - and 10 times more effective than other experimental materials, according to the research.

7 Jul 2010

Celgene signs definitive merger agreement to acquire Abraxis BioScience

Celgene Corporation and Abraxis BioScience Inc. today jointly announced the signing of a definitive merger agreement in which Celgene has agreed to acquire Abraxis BioScience. Under the terms of the merger agreement, each share of Abraxis BioScience common stock will be converted into the right to receive an upfront payment of $58.00 in cash and 0.2617 shares of Celgene common stock.

30 Jun 2010

Sirnaomics receives NIH SBIR grants to advance siRNA therapeutics for critical human diseases

Sirnaomics, Inc. announced today that the company has received two SBIR (Small Business Innovation Research) grants from National Cancer Institute (NCI) and National Institute of Allergy and Infectious Diseases (NIAID), of National Institute of Health (NIH). Sirnaomics, Inc., a biopharmaceutical company founded in early 2007, is dedicated to developing RNA interference (RNAi) therapeutics for treatment of critical human diseases.

30 Jun 2010

BIND Biosciences announces $12.4 million Series C-1 financing

BIND Biosciences, Inc. (BIND), a privately held biopharmaceutical company developing best in class therapeutics based on its proprietary targeted nanotechnology platform, announced today that it has secured a $12.4 Million Series C-1 financing. This financing included all of BIND's current investors (including Polaris Venture Partners, Flagship Ventures, ARCH Venture Partners, NanoDimension and DHK Investments) as well as a new venture investor, Endeavour Vision, and private investors.

29 Jun 2010

Scientists report potential toxicity of nanoparticles in consumer products

Scientists are reporting that particle size affects the toxicity of zinc oxide, a material widely used in sunscreens. Particles smaller than 100 nanometers are slightly more toxic to colon cells than conventional zinc oxide. Solid zinc oxide was more toxic than equivalent amounts of soluble zinc, and direct particle to cell contact was required to cause cell death.

25 Jun 2010

MonoSol Rx, Midatech collaborate to develop peptides for therapeutic delivery utilizing pharmaceutical films

MonoSol Rx, the developer of PharmFilm® drug delivery technology, today announced the expansion of its agreement with Midatech Group (Oxford, UK) to develop nanoparticle-based proteins and peptides for therapeutic delivery utilizing pharmaceutical films. Under the terms of the expanded agreement, MonoSol Rx has made an equity investment in Midatech and Keith Kendall, Executive Vice President and Chief Financial Officer of MonoSol Rx, will join the Midatech Board of Directors.

24 Jun 2010

K-State chemical engineer patents chemical structure to make natural personal care products in lab

A Kansas State University chemical engineer has developed and patented a chemical structure to make all-natural personal care products and purer pharmaceuticals in the laboratory.

23 Jun 2010

Celator announces expansion of research agreement with Cephalon

Celator Pharmaceuticals today announced that it has expanded its research agreement with Cephalon, Inc.. The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management program at Cephalon.

22 Jun 2010

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

The June edition of the Journal of Thoracic Oncology features a study aimed at determining the optimal dose of the chemotherapy drug nab-paclitaxel with carboplatin as a first-line therapy in patients with non-small cell lung cancer. Results will provide researchers with a data needed to guide a phase 3 trial.

16 Jun 2010

Celator presents new data on CPX-351 liposome injection at European Hematology Association congress

Celator Pharmaceuticals today announced that new data from a preclinical leukemia study in mice demonstrate that its lead product, CPX-351 (Cytarabine:Daunorubicin) Liposome Injection, alone or in combination with clofarabine or azacytidine can improve treatment outcomes compared to the combination of either agent with the conventional (unencapsulated) cytarabine:daunorubicin regimen.

15 Jun 2010

Researchers find new way to prevent blindness caused by retinitis pigmentosa

Researchers at the University of Oklahoma Health Sciences Center have found a way to use a radical new type of gene therapy to prevent blindness caused by retinitis pigmentosa, giving hope to the estimated 100,000 Americans who suffer from this debilitating disease.

14 Jun 2010

Multiple presentations on nab-driven chemotherapy at 46th ASCO

Abraxis BioScience, Inc. presented abstracts describing 10 trials of nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension), for the treatment of breast cancer at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

9 Jun 2010

Nanoparticle News and Research

Further Reading

An overview of AAPM annual meeting

Arsenic nanoparticle to combat aggressive type of breast cancer prevalent in young women

Access announces agreement to develop oral formulation of proprietary injectable drugs

Highlights of AAPM 52nd meeting

Lectures on DermaVir to be presented at International Conference on Nanosciences & Nanotechnologies

Midatech, Immunotope form joint venture to develop antigen based products for immune therapies

SurModics to present four scientific posters on drug delivery technologies at CRS Annual Meeting

URI engineers develop new controlled drug delivery system using nanoparticles embedded in liposome

Scientists discover nanoparticle to deliver DNA with minimum toxic effect

Celgene signs definitive merger agreement to acquire Abraxis BioScience

Sirnaomics receives NIH SBIR grants to advance siRNA therapeutics for critical human diseases

BIND Biosciences announces $12.4 million Series C-1 financing

Scientists report potential toxicity of nanoparticles in consumer products

MonoSol Rx, Midatech collaborate to develop peptides for therapeutic delivery utilizing pharmaceutical films

K-State chemical engineer patents chemical structure to make natural personal care products in lab

Celator announces expansion of research agreement with Cephalon

Study aims at determining optimal dose of nab-paclitaxel with carboplatin as first-line therapy for NSCLC

Celator presents new data on CPX-351 liposome injection at European Hematology Association congress

Researchers find new way to prevent blindness caused by retinitis pigmentosa

Multiple presentations on nab-driven chemotherapy at 46th ASCO

A practical guide to lipid nanoparticle formulation and resizing eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

BFEB: Advances in microplate-based assays and analysis

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery